Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Periprocedural Normobaric Hyperoxia With Endovascular Therapy for Acute Ischemic Stroke 6-24 Hours After Last Known Well: A Multicenter Randomized Sham-Controlled Phase 3 Trial

NCT07717216 is registered in ClinicalTrials.gov with Weifang Medical University as lead sponsor.

NCT NCT07717216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07717216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Periprocedural Normobaric Hyperoxia With Endovascular Therapy for Acute Ischemic Stroke 6-24 Hours After Last Known Well: A Multicenter Randomized Sham-Controlled Phase 3 Trial
Lead sponsor
Weifang Medical University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 1, 2029
Enrollment
314 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

endovascular treatment, neuroprotection, normobaric hyperoxia, stroke, acute